VX-5/5378

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameVX-5/5378

Drug Alias Nameanti-CXCL13 chimeric IgG2 mAb (Vaccinex)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionC-X-C motif chemokine 13 inhibitors

TargetsC-X-C motif chemokine 13

Therapy Area/IndicationsMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesVaccinex Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesVaccinex Inc

Active IndicationsN/A

Inactive IndicationsMultiple Sclerosis

ATC CodeN/A